WILMINGTON, Mass. / Mar 13, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments.
A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
| Last Trade: | US$168.22 |
| Daily Change: | -1.59 -0.94 |
| Daily Volume: | 939,659 |
| Market Cap: | US$8.600B |
January 21, 2025 January 16, 2025 December 05, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
